Drug Pipeline

IMP321 Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
3
Active Studies
0
Recruiting
1
Phase 3
3
Top Sponsors
Active Studies by Phase
Phase 3
1
Phase 2
1
Phase 1
1
Active Trials
NCT IDTitleConditionStatus
Phase 3
NCT06726265 Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy… Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Active, Not Recruiting
Phase 2
NCT07102940 Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer Breast Cancer Not Yet Recruiting
Phase 1
NCT03252938 Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors Solid Tumors Active, Not Recruiting
Sponsors Running IMP321 Trials
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (1) Immutep S.A.S. (1) George Washington University (1)
Disease Areas
Non-Small Cell Lung Cancer (NSCLC) (2) Bladder Cancer (1) Lung Cancer (1) Breast Cancer (1)
Get alerts when IMP321 trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free